Edition:
United States

AstraZeneca PLC (AZN.N)

AZN.N on New York Stock Exchange

45.15USD
21 Aug 2019
Change (% chg)

$0.53 (+1.19%)
Prev Close
$44.62
Open
$45.00
Day's High
$45.22
Day's Low
$44.98
Volume
116,413
Avg. Vol
614,981
52-wk High
$45.28
52-wk Low
$35.31

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $85,582.06
Shares Outstanding(Mil.): 2,531.83
Dividend: 0.45
Yield (%): 4.09

Financials

  AZN.N Industry Sector
P/E (TTM): 22.42 29.89 32.67
EPS (TTM): 1.53 -- --
ROI: 7.86 14.89 14.48
ROE: 28.47 16.01 15.78

AstraZeneca Imfinzi combination fails advanced lung cancer study

A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.

7:49am EDT

UPDATE 2-AstraZeneca Imfinzi combination fails advanced lung cancer study

* Trial studied treatment in patients whose cancer had spread

7:35am EDT

CORRECTED-UPDATE 1-AstraZeneca's Imfinzi combination fails advanced lung cancer study

Aug 21 AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations.

5:04am EDT

AstraZeneca's Imfinzi misses main goal of advanced lung cancer study

Aug 21 London-listed drugmaker AstraZeneca Plc said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.

2:22am EDT

UPDATE 2-European shares end lower as Italy's political crisis weighs

* Pandora tops STOXX 600 after keeping FY forecast (Recasts, changes comments; Updates to close)

Aug 20 2019

UPDATE 2-Worries over global trade, Italy lead FTSE 100 lower

* Sainsbury's among handful of blue-chip gainers (Adds news items, analyst comment, updates to closing prices)

Aug 20 2019

China adds 148 drugs to key insurance list: state media

BEIJING/SHANGHAI China on Tuesday added 148 drugs to its list of medicines covered by basic medical insurance schemes, part of a push to lower patients' out-of-pocket costs in one of the world's largest drug markets, state media reported.

Aug 20 2019

China adds 148 drugs to key insurance list - state media

BEIJING/SHANGHAI, Aug 20 China on Tuesday added 148 drugs to its list of medicines covered by basic medical insurance schemes, part of a push to lower patients' out-of-pocket costs in one of the world's largest drug markets, state media reported.

Aug 20 2019

AstraZeneca diabetes drug shows promise in heart failure

AstraZeneca made strides on Tuesday toward its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly.

Aug 20 2019

UPDATE 3-AstraZeneca diabetes drug shows promise in heart failure

* AstraZeneca shares rise 1.7% (Adds analyst, executive comments, background, shares)

Aug 20 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates